Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017:2017:4263017.
doi: 10.1155/2017/4263017. Epub 2017 Jun 1.

Treatment of Neovascular Age-Related Macular Degeneration with Anti-VEGF Agents: Predictive Factors of Long-Term Visual Outcomes

Ana Catarina Pedrosa  1 , Tiago Sousa  2 , João Pinheiro-Costa  1   3 , João Beato  1 , Manuel S Falcão  1   2 , Fernando Falcão-Reis  1   2 , Angela Carneiro  1   2
Affiliations

Treatment of Neovascular Age-Related Macular Degeneration with Anti-VEGF Agents: Predictive Factors of Long-Term Visual Outcomes

Ana Catarina Pedrosa et al. J Ophthalmol. 2017.

Abstract

Purpose: To evaluate the predictive factors of long-term visual outcomes in neovascular age-related macular degeneration (nAMD) treated with antivascular endothelial growth factor (anti-VEGF) agents.

Methods: Unicentric retrospective review of patients with nAMD treated with anti-VEGF agents. Visual outcomes, 12 and 60 months after diagnosis, were evaluated. In an attempt to identify predictive factors of visual outcomes, multiple variables (demographic and epidemiological characteristics, angiographic and tomographic features) were analyzed, at baseline and during follow-up.

Results: One hundred and seventeen patients were included. In multivariate analysis, baseline best-corrected visual acuity was associated with all visual endpoints at 12 and 60 months. Additionally, age, gender, number of injections, and development of subretinal fibrosis during follow-up were also significant predictors of visual outcomes at 60 months.

Conclusions: Several factors can be useful in clinical practice as predictors of visual outcomes in response to anti-VEGF treatment of nAMD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Predictive variables at 12 months. (a) Better BCVA at baseline predicted higher final BCVA score and greater likelihood of achieving 65 ETDRS letters or better, at 12 months. Dashed line = fitted simple linear regression line. (b) Worse BCVA at baseline predicted higher BCVA variation and greater likelihood of achieving a variation greater than 0 ETDRS letters, at 12 months. Dashed lined = fitted simple linear regression line. BCVA, best-corrected visual acuity; ETDRS, early treatment diabetic retinopathy study.
Figure 2
Figure 2
Predictive variables of final best-corrected visual acuity at 60 months. (a) Better BCVA at baseline predicted higher final BCVA score and greater likelihood of achieving 65 ETDRS letters or better, at 60 months. Dashed line = fitted simple linear regression line. (b) Higher number of injections predicted higher final BCVA score, at 60 months. Dashed lined = fitted simple linear regression line. BCVA, best-corrected visual acuity; ETDRS, early treatment diabetic retinopathy study.
Figure 3
Figure 3
Predictive variables of best-corrected visual acuity variation at 60 months. (a) Worse BCVA at baseline predicted higher BCVA variation and greater likelihood of achieving a variation greater than 0 ETDRS letters, at 60 months. Dashed lined = fitted simple linear regression line. (b) Higher number of injections predicted greater likelihood of achieving a BCVA variation greater than 0 ETDRS letters, at 60 months. Dashed lined = fitted simple linear regression line. BCVA, best-corrected visual acuity; ETDRS, early treatment diabetic retinopathy study.
See this image and copyright information in PMC

References

    1. Tsilimbaris M. K., López-Gálvez M. I., Gallego-Pinazo R., Margaron P., Lambrou G. N. Epidemiological and clinical baseline characteristics as predictive biomarkers of response to anti-VEGF treatment in patients with neovascular AMD. Journal of Ophthalmology. 2016;2016:13. doi: 10.1155/2016/4367631.4367631 - DOI - PMC - PubMed
    1. Rosenfeld P. J., Brown D. M., Heier J. S., et al. Ranibizumab for neovascular age-related macular degeneration. The New England Journal of Medicine. 2006;355(14):1419–1431. doi: 10.1056/NEJMoa054481. - DOI - PubMed
    1. Brown D. M., Kaiser P. K., Michels M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. The New England Journal of Medicine. 2006;355(14):1432–1444. doi: 10.1056/NEJMoa062655. - DOI - PubMed
    1. Kaiser P. K., Brown D. M., Zhang K., et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. American Journal of Ophthalmology. 2007;144(6):850–857. doi: 10.1016/j.ajo.2007.08.012. - DOI - PubMed
    1. Boyer D. S., Antoszyk A. N., Awh C. C., et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(2):246–252. doi: 10.1016/j.ophtha.2006.10.045. - DOI - PubMed